Amaç: Bu çalışmada, etkileri henüz meme kanseri kök hücrelerinde araştırılmamış olan trabektedinin (ET743, Yondelis®) sitotoksik ve apoptotik etkileri MCF-7 hücreleri ve bu hücrelerden izole edilen CD44+/CD24- meme kanseri kök hücreleri üzerinde karşılaştırmalı olarak araştırılmıştır. Gereç ve Yöntemler: CD44+/CD24- belirteçlerine sahip meme kanseri kök hücreleri MCF-7 hücre kültüründen akış sitometri metodu ile izole edildi. Trabektedinin MCF-7 ve CD44+/CD24- meme kanseri kök hücrelerinin canlılığı üzerindeki etkisini belirlemek üzere XTT testi kullanıldı. Trabektedinin, hücrelerin canlılığı üzerindeki etkisi konsantrasyona ve zamana bağlı olarak ölçüldü. Apoptotik etki DNA fragment miktarının ölçümüyle, mitokondriyal membran potansiyelinde meydana gelen değişimler ise tetrametilrodamin etil ester (TMRE) boyamasıyla belirlendi. Bulgular: Trabektedin, hücre canlılığını MCF-7 meme kanseri ve CD44+/CD24- meme kanseri kök hücre gruplarının her ikisinde de konsantrasyona ve zamana bağlı olarak inhibe etti. MCF-7 hücreleri 48. saatteki IC50 konsantrasyonları için 4,52±0,7 nM, CD44+/CD24- hücreleri için ise 1,23±1,2 nM olarak hesaplandı. IC50 konsantrasyonları değerlendirildiğinde, CD44+/CD24- meme kanseri kök hücrelerinin trabektedine MCF-7'den daha hassas olduğu tespit edildi. Kontrol grubundaki hücrelerin mitokondrileri floresans TMRE boyası ile boyanırken, trabektedinle muamele edilen her iki hücre popülasyonunun da boyanma miktarlarında azalma gözlendi. Trabektedinin CD44+/CD24- meme kanseri kök hücrelerinde apoptozu daha etkin bir şekilde indüklediği belirlendi. Sonuç: Elde edilen veriler, trabektedinin meme kanseri hücre grubunda olduğu gibi meme kanseri kök hücrelerinde de sitotoksik ve apoptotik etkisi olduğunu ortaya koymuştur. Bu sonuçlar, trabektedinin meme kanseri için potansiyel bir terapötik olabileceğini göstermektedir. Ancak trabektedinin meme kanseri kök hücreleri üzerindeki etkilerinin daha detaylı olarak çalışıldığı araştırmalara ihtiyaç vardır.
Anahtar Kelimeler: Trabektedin; meme kanseri; MCF-7; kanser kök hücresi; sitotoksisite; apoptozis
Objective: In this study, effect of trabectedin (ET743, Yondelis®) was investigated on the viability of MCF-7 cells and CD44+/CD24- breast cancer stem cells. Material and Methods: CD44+/CD24- breast cancer stem cells were isolated from MCF-7 cells by using flow cytometry. XTT test was used to investigate the effect of trabectedin on the viability of MCF-7 and CD44+/ CD24- breast cancer stem cells. Apoptotic effect of trabectedin was investigated by measuring DNA fragmentation and changes in mitochondrial membrane potential were determined by tetramethylrhodamine ethyl ester (TMRE) staining. Results: Trabectedin inhibited the cell viability of both MCF-7 breast cancer and CD44+/CD24- breast cancer stem cells in a concentration and time dependent manner. IC50 concentrations at 48 h was calculated as 4.52±0.7 nM for MCF-7 cells and 1.23±1.2 nM for CD44+/CD24- cells. It was found that breast cancer stem cells were more sensitive to trabectedin than MCF-7 cancer cells. Cells in control group were stained with fluorescent TMRE stain but the staining was less in the both cell groups that were treated with the IC50 concentrations of trabectedin. It was shown that trabectedin induced more apoptotic cells in CD44+/CD24- breast cancer stem cells. Conclusion: According to the current data, it was shown that trabectedin induced cytotoxicity and apoptosis in breast cancer stem cells as well as MCF-7 cancer cells in a concentration and time dependent manner. These data indicates that trabectedin might be a potential therapeutic for breast cancer. However, more detailed studies investigating the effects of trabectedin on breast cancer stem cells are needed.
Keywords: Trabectedin; breast cancer; MCF-7; cancer stem cell; cytotoxicity; apoptosis
- Islam F, Gopalan V, Smith RA, Lam AK. Translational potential of cancer stem cells: a review of the detection of cancer stem cells and their roles in cancer recurrence and cancer treatment. Exp Cell Res. 2015;335(1):135-47. [Crossref] [PubMed]
- Jin X, Jin X, Kim H. Cancer stem cells and differentiation therapy. Tumour Biol. 2017; 39(10):1010428317729933. [Crossref] [PubMed]
- Yu Z, Pestell TG, Lisanti MP, Pestell RG. Cancer stem cells. Int J Biochem Cell Biol. 2012;44(12):2144-51. [Crossref] [PubMed] [PMC]
- La Porta CA. Mechanism of drug sensitivity and resistance in melanoma. Curr Cancer Drug Targets. 2009;9(3):391-7. [Crossref] [PubMed]
- Nami B, Wang Z. HER2 in breast cancer stemness: a negative feedback loop towards trastuzumab resistance. Cancers (Basel). 2017;9(5). [Crossref] [PubMed] [PMC]
- Tume L, Paco K, Ubidia-Incio R, Moya J. CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy. Gac Mex Oncol. 2016;15(1):22-30. [Crossref]
- D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther. 2010;9(8):2157-63. [Crossref] [PubMed]
- Larsen AK, Galmarini CM, D'Incalci M. Unique features of trabectedin mechanism of action. Cancer Chemother Pharmacol. 2016;77(4): 663-71. [Crossref] [PubMed]
- Martinez-Cruzado L, Tornin J, Rodriguez A, Santos L, Allonca E, Fernandez-Garcia MT, et al. Trabectedin and campthotecin synergistically eliminate cancer stem cells in cell-of-origin sarcoma models. Neoplasia. 2017; 19(6):460-70. [Crossref] [PubMed] [PMC]
- Acikgoz E, Guven U, Duzagac F, Uslu R, Kara M, Soner BC, et al. Enhanced G2/M arrest, caspase related apoptozis and reduced E-cadherin dependent intercellular adhesion by trabectedin in prostate cancer stem cells. PLoS One. 2015;10(10):e0141090. [Crossref] [PubMed] [PMC]
- Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol. 2012; 2012:708036. [Crossref] [PubMed] [PMC]
- Ercan C, van Diest PJ, Vooijs M. Mammary development and breast cancer: the role of stem cells. Curr Mol Med. 2011;11(4):270-85. [Crossref] [PubMed] [PMC]
- Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983-8. [Crossref] [PubMed] [PMC]
- Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006;8(5):R59. [Crossref] [PubMed] [PMC]
- Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res. 2005;11(3):1154-9.
- Radpour R. Tracing and targeting cancer stem cells: new venture for personalized molecular cancer therapy. World J Stem Cells. 2017;9(10):169-78. [Crossref] [PubMed] [PMC]
- Peraldo-Neia C, Cavalloni G, Soster M, Gammaitoni L, Marchio S, Sassi F, et al. Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. BMC Cancer. 2014;14:918. [Crossref] [PubMed] [PMC]
- Mirabella M, Di Giovanni S, Silvestri G, Tonali P, Servidei S. Apoptosis in mitochondrial encephalomyopathies with mitochondrial DNA mutations: a potential pathogenic mechanism. Brain. 2000;123(Pt 1):93-104. [Crossref] [PubMed]
.: Process List